Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion
Status:
Withdrawn
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Heart Failure is a growing and challenging public health concern in the United States. Heart
failure commonly manifests as a syndrome of salt and water retention. Arginine vasopressin is
a peptide hormone that is intimately involved in salt and water homeostasis. AVP is released
into the circulation in response low blood volume and hypernatraemia. Despite fluid overload,
vasopressin levels are often inappropriately elevated in patients with heart failure and LV
dysfunction. Data suggest that vasopressin may also contribute to the deleterious circulatory
response in patients with heart failure and play a role in the development and progression of
the disease process. In their study, Udelson et al. showed that vasopressin receptor
antagonism with Conivaptan resulted in significant diuresis with stable hemodynamics in
advanced heart failure patients. Currently Intravenous diuretics and vasodilators are the
standard of care in treating patients with acute decompensated heart failure. We will be
studying the renal and diuretic effects of add on therapy with intravenous Conivaptan in
patients receiving intravenous Nesiritide and intravenous diuretics.